The extensive research, spanning four years and conducted by a multidisciplinary team from UMH’s Institute of Neurosciences, along with affiliations such as ISABIAL and RIAPAD, addresses a critical gap in AUD pharmacotherapy. Despite the significant global burden of AUD, responsible for approximately 2.6 million deaths annually, existing pharmacotherapies fail to maintain long-term abstinence in the majority of patients. Alarmingly, relapse rates hover around 70% within the first year post-treatment, underscoring the urgent demand for novel pharmacological interventions.

Central to the innovation behind MCH11 is the modulation of the endocannabinoid system (ECS), a complex neuromodulatory network that intricately connects the brain with various physiological processes regulating pleasure, motivation, and stress responses. In individuals afflicted with AUD, dysregulation of the ECS is evident, notably through diminished levels of 2-arachidonoylglycerol (2-AG), an endogenous cannabinoid associated with well-being and impulse regulation. MCH11 operates as a selective inhibitor of monoacylglycerol lipase, the enzyme responsible for degrading 2-AG, thereby elevating its cerebral concentrations to restore homeostatic balance.

Through the inhibition of MAGL, MCH11 effectively enhances endogenous 2-AG signaling, translating into significant reductions in ethanol consumption and the compulsion to drink, as observed in controlled animal studies. These effects were accompanied by a reduction in withdrawal symptoms, a major hurdle in AUD recovery. Intriguingly, behavioral assessments revealed that treatment with MCH11 imparted anxiolytic and antidepressant-like effects, suggesting a dual therapeutic action addressing both dependence and comorbid affective disorders without compromising motor or cognitive faculties.

Sex-dependent responses emerged as a compelling dimension of MCH11’s pharmacodynamics. Male mice exhibited significant reductions in ethanol intake and enhanced behavioral outcomes at low to medium doses, whereas female mice required higher dosages to achieve comparable benefits. This divergence not only highlights biological sex as a crucial variable in addiction therapy efficacy but also advocates for sex-specific dosing regimens in future clinical translations.

At the molecular level, quantitative PCR analyses demonstrated that MCH11 rectifies gene expression perturbations associated with AUD in both sexes, albeit with dose-dependent variance between males and females. Genes implicated in neurotransmitter regulation, neuroinflammatory pathways, and synaptic plasticity were among those normalized, providing mechanistic insights into how MCH11 counters alcohol-induced neurobiological alterations.

Beyond monotherapy, the research team investigated the synergistic potential of combining MCH11 with topiramate, an FDA-approved antiepileptic repurposed for combating alcohol dependence. The combinatorial regimen exhibited superior efficacy in attenuating ethanol use and modifying drinking motivation, surpassing outcomes observed with either compound alone. This finding paves the way for developing multifaceted, personalized pharmacological approaches embracing both innovative agents and established medications.

Although these preliminary results stem from animal experimentation, the implications for human AUD treatment are substantial. MCH11’s capacity to selectively ameliorate alcohol consumption behaviors and associated neuropsychiatric symptoms without detrimental side effects positions it as a frontrunner in next-generation pharmacotherapies. Importantly, the nuanced sex-dependent variations underscore the necessity for precision medicine paradigms tailoring interventions to individual biological profiles.

The translational journey from murine models to clinical application remains a formidable challenge. Nevertheless, the current findings provide a robust foundation for subsequent pharmacokinetic, toxicological, and eventually clinical trials to explore MCH11’s safety, efficacy, and optimized dosing in humans. UMH’s interdisciplinary team remains committed to advancing this promising candidate through the drug development pipeline.

In conclusion, the discovery of MCH11 ushers in a new era of neuropharmacological intervention for alcohol use disorder, harnessing the therapeutic potential of the endocannabinoid system. By restoring neurochemical balance and mitigating maladaptive behaviors intrinsic to addiction, MCH11 exemplifies the synergy between molecular innovation and clinical needs. Its sex-specific efficacy further challenges the convention, advocating for more individualized treatment frameworks to combat the pervasive and complex disorder that is alcoholism.

This research was spearheaded by lead author Abraham Torregrosa and co-authored by María García Gutiérrez, Daniela Navarro, Francisco Navarrete, and Professor Jorge Manzanares. The study was generously funded by Spain’s Ministry of Science, Innovation and Universities, the State Research Agency, the Carlos III Health Institute’s RIAPAD network, and ISABIAL.

Subject of Research: Animals
Article Title: MCH11, a new monoacylglycerol lipase inhibitor, reduces ethanol consumption and motivation to drink in mice, with sex-dependent differences. Biomedicine & Pharmacotherapy
News Publication Date: 21-Oct-2025
Web References: 10.1016/j.biopha.2025.118662
Image Credits: Instituto de Neurociencias UMH-CSIC
Keywords: Alcohol abuse, Substance abuse, Human behavior, Substance related disorders, Alcoholism, Diseases and disorders, Antidepressants, Medications, Drug therapy, Drug dosage, Drug development, Neuropharmacology, Molecular neuropharmacology

Alcohol use disorder represents a profound public health challenge, characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. Yet despite its prevalence, the majority of individuals with AUD are not engaged in effective treatment regimens. The complex interplay of addiction biology, social determinants, and healthcare access barriers creates a treatment gap that has persisted for decades. The new Boston University study offers compelling evidence that integrating pharmacotherapy initiation into inpatient care protocols may be an effective strategy to close this gap and improve patient outcomes.

The study methodically compared two formulations of naltrexone: an oral pill taken daily, and an extended-release injectable administered monthly. Both forms act as opioid antagonists that modulate the brain’s reward circuitry by blocking the euphoric effects of alcohol, thereby decreasing cravings and heavy drinking episodes. Until now, randomized clinical trial data directly comparing these two formulations’ real-world effectiveness had been lacking. The current research fills that void by enrolling 248 hospitalized individuals diagnosed with AUD and randomizing them to receive either the oral or injectable naltrexone at discharge, then carefully tracking their alcohol consumption over the subsequent three months.

Remarkably, both formulations yielded substantial reductions in heavy drinking days over the three-month follow-up. Patients adhering to the daily oral regimen experienced approximately a 38 percentage-point drop in heavy drinking within the prior 30 days, while those receiving the extended-release injectable saw an even more pronounced 46 percentage-point decrease. This equivalence in clinical efficacy underscores the versatility of naltrexone therapy, allowing personalized choices based on patient preferences, tolerability, and logistical considerations without compromising therapeutic benefits.

One of the notable technical insights revealed by this trial concerns medication adherence. Consistent with earlier observations, adherence rates were modestly higher for the injectable naltrexone, likely attributable to its once-monthly dosing regimen that circumvents the challenge of daily pill-taking. However, the study authors highlight that adherence in the context of a clinical trial, with structured follow-up, may not fully recapitulate real-world conditions where patients must negotiate complex socioeconomic and healthcare system barriers. Still, the findings suggest that offering patients flexibility in selecting their preferred dosage form, informed by careful clinician-patient dialogue, could optimize adherence and enhance outcomes.

Beyond the pharmacokinetic and behavioral dimensions, the study sheds light on the economic and logistical trade-offs intrinsic to each formulation. The injectable naltrexone incurs notably higher upfront costs—exceeding $1,000 per injection when billed through Medicare Part B—compared to approximately $38 for 30 days of oral pills dispensed under Medicare Part D. Moreover, injectable administration necessitates clinic visits for intramuscular injection, potentially imposing additional access hurdles. These cost and operational factors complicate decisions around widespread adoption, especially in resource-constrained hospital settings. The study thus advocates for nuanced policy and reimbursement frameworks that can accommodate both formulations to maximize patient-centered care.

The researchers also examined clinical endpoints beyond consumption patterns, notably acute hospital readmissions and AUD-related healthcare utilization during the three-month post-discharge window. Interestingly, the initiation of naltrexone in either formulation did not correlate with statistically significant differences in hospital visits within this timeframe. This observation suggests that while naltrexone effectively reduces heavy drinking—a key driver of morbidity—the broader impact on healthcare utilization may require longer follow-up durations or complementary psychosocial interventions alongside pharmacotherapy to manifest measurable reductions.

A striking feature of this research is the recognition of the unique opportunity hospitals provide to intercept a traditionally underserved population. Hospitalizations often represent critical “teachable moments” when patients may be more receptive to interventions for their AUD, given the acute health consequences that precipitated their admission. Yet historically, AUD has suffered from underdiagnosis and suboptimal management in inpatient settings, overshadowed by the immediacy of acute medical issues. By embedding AUD pharmacotherapy into discharge planning, hospitals can pivot from episodic care towards sustained management of this chronic illness.

Dr. Jeffrey Samet, the study’s corresponding author and a clinician-scientist with profound expertise in addiction medicine, underscores the transformative potential of these findings. He contends that initiating evidence-based treatment during hospitalization can catalyze durable improvements in AUD outcomes, effectively bridging a care gap that has persisted despite well-characterized pharmacologic options. This robust clinical trial provides the empirical foundation necessary to reframe hospital care protocols and incentivize system-wide integration of addiction treatment services.

The study also honors the legacy of Dr. Richard Saitz, a pioneering figure in addiction research and the original principal investigator. His vision and meticulous scientific rigor continue to influence the field profoundly. Completion and publication of these findings posthumously reflect a tribute to his commitment to advancing accessible, compassionate care for people with substance use disorders.

Funding for this research was provided by the National Institute on Alcohol Abuse and Alcoholism, supplemented by contributions from Alkermes and the United States Drug Testing Laboratories. The interdisciplinary research team comprised experts spanning Boston University’s School of Public Health and School of Medicine, Boston Medical Center, South Shore Hospital, and the University of Pittsburgh School of Medicine, reflecting a collaborative approach essential for tackling complex addiction challenges.

Looking ahead, the research team emphasizes the necessity of complementary studies to unpack patient-centered factors influencing medication adherence, including social determinants such as housing stability and access to post-discharge care. Understanding patient preferences in formulation choice and optimizing delivery models in diverse clinical settings remain vital for translating these clinical trial successes into real-world impact.

Ultimately, this study delivers a compelling call to action: effective, evidence-based pharmacologic treatments for alcohol use disorder exist and can be successfully initiated in hospital settings. Moving beyond the siloed management of acute issues, healthcare systems must embrace addiction treatment as a fundamental component of routine inpatient care. Such paradigm shifts stand to alleviate the immense individual and societal burdens imposed by AUD and pave the way towards more equitable and effective public health interventions.

Subject of Research: People

Article Title: Oral vs Extended-Release Naltrexone for Hospitalized Patients with Alcohol Use Disorder

News Publication Date: 21-Apr-2025

Web References:

• https://doi.org/10.1001/jamainternmed.2025.0522
• https://www.niaaa.nih.gov/alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-disorder-aud-united-states-age-groups-and-demographic-characteristics

References:
Magane K, Cheng DM, Samet JH, et al. Oral vs Extended-Release Naltrexone for Hospitalized Patients with Alcohol Use Disorder. JAMA Internal Medicine. Published April 21, 2025. doi:10.1001/jamainternmed.2025.0522

Keywords:
Alcoholism; Hospitals; Clinical research; Public health; Drug therapy; Drug studies; Drug costs; Health care delivery; Scientific data; Urban populations; Drug delivery systems; Addiction; Substance related disorders